AI Engines For more Details: Perplexity Kagi Labs You
Anticoagulation: Dicumarol exerts its therapeutic effect by interfering with the body's natural blood clotting process. It inhibits the action of vitamin K epoxide reductase, an enzyme involved in the synthesis of vitamin K-dependent clotting factors in the liver. By blocking this enzyme, dicumarol reduces the production of clotting factors such as prothrombin (factor II) and factors VII, IX, and X, which are essential for blood clot formation.
Prevention of Thrombosis: Dicumarol was historically used for the prevention and treatment of various thrombotic disorders, including deep vein thrombosis (DVT), pulmonary embolism (PE), atrial fibrillation (AF), and mechanical heart valve replacement. By inhibiting blood clot formation, dicumarol helps prevent the formation or progression of thrombi (blood clots) in the veins or arteries, reducing the risk of thromboembolic events such as strokes, heart attacks, and pulmonary emboli.
Warfarin Analog: Dicumarol is structurally similar to warfarin, another vitamin K antagonist anticoagulant medication that is more commonly used today. Warfarin has largely replaced dicumarol in clinical practice due to its greater potency, predictable pharmacokinetics, and wider therapeutic index. However, dicumarol paved the way for the development of warfarin and other vitamin K antagonists as essential medications for anticoagulation therapy.
Monitoring: Like other vitamin K antagonists, dicumarol requires careful monitoring of anticoagulant activity to ensure optimal therapeutic effect and minimize the risk of bleeding complications. This is typically accomplished by measuring the prothrombin time (PT) or international normalized ratio (INR) regularly and adjusting the dosage of dicumarol as needed to maintain the desired level of anticoagulation.
Side Effects and Complications: Dicumarol therapy carries a risk of bleeding complications, including minor bleeding (such as nosebleeds or bruising) and more serious bleeding events (such as gastrointestinal bleeding or intracranial hemorrhage). The risk of bleeding is influenced by various factors, including the intensity of anticoagulation, concomitant use of other medications, underlying medical conditions, and individual patient characteristics.
Drug Interactions: Dicumarol interacts with numerous medications, foods, and supplements that can affect its anticoagulant activity. It's important for individuals taking dicumarol to be aware of potential interactions and to consult with their healthcare provider or pharmacist before starting or stopping any medications or supplements.
Rank | Probiotic | Impact |
---|---|---|
species | Akkermansia muciniphila | Reduces |
species | Bifidobacterium longum | Reduces |
species | Escherichia coli | Reduces |
subspecies | Bifidobacterium longum subsp. infantis | Reduces |
subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
---|---|---|---|
Acne | 0 | 0 | |
ADHD | 4 | 0 | 0 |
Age-Related Macular Degeneration and Glaucoma | 0.1 | 0.5 | -4 |
Allergic Rhinitis (Hay Fever) | 2.6 | 0 | 0 |
Allergies | 2.8 | 2.4 | 0.17 |
Allergy to milk products | 1.6 | 0.6 | 1.67 |
Alopecia (Hair Loss) | 1.3 | 1.3 | |
Alzheimer's disease | 3.7 | 2.5 | 0.48 |
Amyotrophic lateral sclerosis (ALS) Motor Neuron | 1.9 | 0.7 | 1.71 |
Ankylosing spondylitis | 3.1 | 2.4 | 0.29 |
Anorexia Nervosa | 0.5 | 1.5 | -2 |
Antiphospholipid syndrome (APS) | 1.7 | 1.7 | |
Asthma | 0.6 | 0.6 | 0 |
Atherosclerosis | 1 | 1.5 | -0.5 |
Atrial fibrillation | 2.1 | 2.1 | 0 |
Autism | 8.1 | 5.1 | 0.59 |
Barrett esophagus cancer | 0.5 | 0.5 | 0 |
benign prostatic hyperplasia | 0.1 | 0.1 | |
Bipolar Disorder | 1.5 | 0.5 | 2 |
Brain Trauma | 0.1 | 0.5 | -4 |
Carcinoma | 2.8 | 2.2 | 0.27 |
Celiac Disease | 2 | 2.2 | -0.1 |
Cerebral Palsy | 1.1 | 1 | 0.1 |
Chronic Fatigue Syndrome | 5.1 | 4.7 | 0.09 |
Chronic Kidney Disease | 2.1 | 0.1 | 20 |
Chronic Lyme | 0.5 | -0.5 | |
Chronic Obstructive Pulmonary Disease (COPD) | 3 | 3 | |
Chronic Urticaria (Hives) | 1.3 | 2.1 | -0.62 |
Coagulation / Micro clot triggering bacteria | 1.3 | 1 | 0.3 |
Colorectal Cancer | 5.7 | 0.1 | 56 |
Constipation | 0.8 | 0.1 | 7 |
Coronary artery disease | 1.5 | 0.1 | 14 |
COVID-19 | 9.4 | 11.1 | -0.18 |
Crohn's Disease | 7.6 | 3.7 | 1.05 |
cystic fibrosis | 0.3 | 0.5 | -0.67 |
deep vein thrombosis | 0.3 | 0.9 | -2 |
Depression | 8.7 | 4.1 | 1.12 |
Dermatomyositis | 0.5 | 0 | 0 |
Eczema | 1.1 | 3 | -1.73 |
Endometriosis | 2 | 0.9 | 1.22 |
Eosinophilic Esophagitis | 0.5 | 0 | 0 |
Epilepsy | 2.8 | 2.2 | 0.27 |
Fibromyalgia | 3 | 3 | 0 |
Functional constipation / chronic idiopathic constipation | 4.5 | 3.9 | 0.15 |
gallstone disease (gsd) | 1.7 | 0.5 | 2.4 |
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 1.7 | 0.7 | 1.43 |
Generalized anxiety disorder | 1.9 | 1 | 0.9 |
giant cell arteritis | 0.5 | -0.5 | |
Glioblastoma | 0.5 | -0.5 | |
Graves' disease | 1.1 | 0.3 | 2.67 |
Halitosis | 1 | 0.5 | 1 |
Hashimoto's thyroiditis | 0.7 | 0.5 | 0.4 |
Hidradenitis Suppurativa | 1 | 0 | 0 |
Histamine Issues,Mast Cell Issue, DAO Insufficiency | 1.2 | 0.6 | 1 |
hypercholesterolemia (High Cholesterol) | 1 | 0.1 | 9 |
hyperglycemia | 0.1 | 1.2 | -11 |
Hyperlipidemia (High Blood Fats) | 0.2 | 0.1 | 1 |
hypersomnia | 0.1 | -0.1 | |
hypertension (High Blood Pressure | 2.2 | 2.6 | -0.18 |
Hypothyroidism | 0.1 | -0.1 | |
Hypoxia | 1 | 1 | |
IgA nephropathy (IgAN) | 5.4 | -5.4 | |
Inflammatory Bowel Disease | 5.3 | 5.7 | -0.08 |
Insomnia | 1.1 | 0.5 | 1.2 |
Intelligence | 1.5 | 1 | 0.5 |
Intracranial aneurysms | 1.5 | 0.1 | 14 |
Irritable Bowel Syndrome | 3.8 | 3.4 | 0.12 |
Liver Cirrhosis | 3.8 | 2.1 | 0.81 |
Long COVID | 6.8 | 4.9 | 0.39 |
Lung Cancer | 1.1 | 0.7 | 0.57 |
ME/CFS with IBS | 1 | 0.9 | 0.11 |
ME/CFS without IBS | 2.2 | 1.8 | 0.22 |
Menopause | 1 | 1 | |
Metabolic Syndrome | 7.2 | 6 | 0.2 |
Mood Disorders | 10.3 | 4.1 | 1.51 |
multiple chemical sensitivity [MCS] | 1.6 | 0.1 | 15 |
Multiple Sclerosis | 4.4 | 6.4 | -0.45 |
Multiple system atrophy (MSA) | 1.2 | 0.5 | 1.4 |
Neuropathy (all types) | 0.6 | 0.1 | 5 |
neuropsychiatric disorders (PANDAS, PANS) | 0.7 | 0.7 | |
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 2.4 | 1.8 | 0.33 |
NonCeliac Gluten Sensitivity | 0 | 0 | |
Obesity | 6.2 | 3.9 | 0.59 |
obsessive-compulsive disorder | 7.1 | 3.2 | 1.22 |
Osteoarthritis | 3.4 | 0.4 | 7.5 |
Osteoporosis | 1.6 | 0.7 | 1.29 |
pancreatic cancer | 1 | 1 | |
Parkinson's Disease | 1.5 | 2.6 | -0.73 |
Polycystic ovary syndrome | 2.3 | 1.9 | 0.21 |
Postural orthostatic tachycardia syndrome | 0.5 | 0 | 0 |
Premenstrual dysphoric disorder | 0.2 | 0.5 | -1.5 |
primary biliary cholangitis | 0.1 | 1.1 | -10 |
Psoriasis | 3.2 | 3.1 | 0.03 |
rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 5.5 | 3.2 | 0.72 |
Rosacea | 0.4 | 0.5 | -0.25 |
Schizophrenia | 4.7 | 1 | 3.7 |
scoliosis | 0.4 | -0.4 | |
Sjögren syndrome | 2.7 | 2.2 | 0.23 |
Sleep Apnea | 1 | 0.6 | 0.67 |
Small Intestinal Bacterial Overgrowth (SIBO) | 1.2 | 0 | 0 |
Stress / posttraumatic stress disorder | 2.4 | 0.8 | 2 |
Systemic Lupus Erythematosus | 4.7 | 1 | 3.7 |
Tic Disorder | 1.2 | 1.2 | 0 |
Tourette syndrome | 0.1 | 0.5 | -4 |
Type 1 Diabetes | 3.4 | 1.2 | 1.83 |
Type 2 Diabetes | 7 | 6.7 | 0.04 |
Ulcerative colitis | 2 | 5.4 | -1.7 |
Unhealthy Ageing | 5.7 | 0.6 | 8.5 |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.
Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 Β§β―1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.